CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases,…
KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for R/R NPM1-mutated AML, is now commercially available in the United…
KOLKATA, India, Sept. 25, 2025 /PRNewswire/ -- In a major milestone for cancer care in Eastern India, doctors at Apollo…